EP0271521A4 - Lipopolysaccharide and natural factor compositions for anti-tumor therapy and method of treatment. - Google Patents
Lipopolysaccharide and natural factor compositions for anti-tumor therapy and method of treatment.Info
- Publication number
- EP0271521A4 EP0271521A4 EP19870903576 EP87903576A EP0271521A4 EP 0271521 A4 EP0271521 A4 EP 0271521A4 EP 19870903576 EP19870903576 EP 19870903576 EP 87903576 A EP87903576 A EP 87903576A EP 0271521 A4 EP0271521 A4 EP 0271521A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- lps
- tumor
- tnf
- agent
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000002158 endotoxin Substances 0.000 title claims abstract description 138
- 229920006008 lipopolysaccharide Polymers 0.000 title claims abstract description 138
- 230000000259 anti-tumor effect Effects 0.000 title claims abstract description 23
- 238000002560 therapeutic procedure Methods 0.000 title claims abstract description 9
- 238000011282 treatment Methods 0.000 title claims description 25
- 238000000034 method Methods 0.000 title claims description 20
- 239000000203 mixture Substances 0.000 title claims description 18
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 106
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims abstract description 72
- 229960000905 indomethacin Drugs 0.000 claims abstract description 36
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 18
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 17
- 231100000252 nontoxic Toxicity 0.000 claims abstract description 17
- 230000003000 nontoxic effect Effects 0.000 claims abstract description 17
- 230000004044 response Effects 0.000 claims abstract description 16
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims abstract description 13
- 229960004397 cyclophosphamide Drugs 0.000 claims abstract description 13
- 229940127089 cytotoxic agent Drugs 0.000 claims abstract description 9
- 210000000987 immune system Anatomy 0.000 claims abstract description 9
- 102000004211 Platelet factor 4 Human genes 0.000 claims abstract description 6
- 108090000778 Platelet factor 4 Proteins 0.000 claims abstract description 6
- 108010002352 Interleukin-1 Proteins 0.000 claims description 19
- 230000000694 effects Effects 0.000 claims description 17
- 108010002350 Interleukin-2 Proteins 0.000 claims description 14
- 231100000419 toxicity Toxicity 0.000 claims description 14
- 230000001988 toxicity Effects 0.000 claims description 14
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 claims description 7
- 241000124008 Mammalia Species 0.000 claims description 7
- 239000002089 prostaglandin antagonist Substances 0.000 claims description 3
- 230000000638 stimulation Effects 0.000 claims description 3
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 claims description 2
- KPHWPUGNDIVLNH-UHFFFAOYSA-M diclofenac sodium Chemical compound [Na+].[O-]C(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl KPHWPUGNDIVLNH-UHFFFAOYSA-M 0.000 claims description 2
- 229940063674 voltaren Drugs 0.000 claims description 2
- 101000959820 Homo sapiens Interferon alpha-1/13 Proteins 0.000 claims 8
- 239000003102 growth factor Substances 0.000 claims 1
- 239000005445 natural material Substances 0.000 claims 1
- 230000002195 synergetic effect Effects 0.000 claims 1
- 210000002966 serum Anatomy 0.000 abstract description 18
- 230000001580 bacterial effect Effects 0.000 abstract description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 87
- 102000003390 tumor necrosis factor Human genes 0.000 description 87
- 241000699670 Mus sp. Species 0.000 description 33
- 206010028851 Necrosis Diseases 0.000 description 31
- 230000017074 necrotic cell death Effects 0.000 description 31
- 206010054094 Tumour necrosis Diseases 0.000 description 20
- 241001465754 Metazoa Species 0.000 description 19
- 102000014150 Interferons Human genes 0.000 description 18
- 108010050904 Interferons Proteins 0.000 description 18
- 229940079322 interferon Drugs 0.000 description 18
- 241000699666 Mus <mouse, genus> Species 0.000 description 12
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 12
- 102000000589 Interleukin-1 Human genes 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 11
- 230000001404 mediated effect Effects 0.000 description 11
- 201000011510 cancer Diseases 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- 210000004881 tumor cell Anatomy 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 9
- 210000000822 natural killer cell Anatomy 0.000 description 9
- 210000001744 T-lymphocyte Anatomy 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- 102000000588 Interleukin-2 Human genes 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 230000007123 defense Effects 0.000 description 6
- 239000000411 inducer Substances 0.000 description 6
- 230000036210 malignancy Effects 0.000 description 6
- 150000003180 prostaglandins Chemical class 0.000 description 6
- 230000006051 NK cell activation Effects 0.000 description 5
- 230000001154 acute effect Effects 0.000 description 5
- 230000008030 elimination Effects 0.000 description 5
- 238000003379 elimination reaction Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000028993 immune response Effects 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 231100000331 toxic Toxicity 0.000 description 5
- 230000002588 toxic effect Effects 0.000 description 5
- 230000009471 action Effects 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000008260 defense mechanism Effects 0.000 description 4
- 238000009169 immunotherapy Methods 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 3
- 238000011725 BALB/c mouse Methods 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 108010074338 Lymphokines Proteins 0.000 description 3
- 102000008072 Lymphokines Human genes 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000002648 combination therapy Methods 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 230000008629 immune suppression Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000011287 therapeutic dose Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000003162 effector t lymphocyte Anatomy 0.000 description 2
- 230000008713 feedback mechanism Effects 0.000 description 2
- 230000005934 immune activation Effects 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000006433 tumor necrosis factor production Effects 0.000 description 2
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- -1 IL-I Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101100340186 Mus musculus Ido1 gene Proteins 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 101710097943 Viral-enhancing factor Proteins 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001715 anti-suppressor Effects 0.000 description 1
- 230000006023 anti-tumor response Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 230000002153 concerted effect Effects 0.000 description 1
- 210000000448 cultured tumor cell Anatomy 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 230000009066 down-regulation mechanism Effects 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 102000057041 human TNF Human genes 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 239000012642 immune effector Substances 0.000 description 1
- 230000037189 immune system physiology Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000013586 microbial product Substances 0.000 description 1
- 230000002956 necrotizing effect Effects 0.000 description 1
- 230000002560 nonimmunologic effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000135 prohibitive effect Effects 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 231100000925 very toxic Toxicity 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/195—Chemokines, e.g. RANTES
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2006—IL-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Definitions
- SUMMARY Lipopolysaccharide or variants thereof can be used together with such anti-tumor agents as exogenous TNF as effective anti-tumor agents at non-toxic levels.
- Inhibitors such as indomethacin which block agents, such as prostaglandin which act against immune system activation or agents which act as against suppressor cell activation such as cyclophosphamide can be used as well.
- Fig. 1 shows synergism in causing necrosis and regression of tumors with LPS and TNF, also with TNF and LPS with INDO (Indomethacin).
- Fig. 2 shows correlation between tumor necrosis and subsequent regression of tumors.
- Fig. 1 Synergism between TNF and LPS is causing necrosis and regression of tumor transplants in mice. Animals were treated in addition to TNF and LPS with INDO.
- Fig. 2 Correlation between tumor necrosis and subsequent regression of tumors, the data obtained with LPS (0) relates the degrees of necrosis in individual mice to the regression of the same tumors. In the experiments with TNF we had not assessed individual mice for necrosis and regression but only groups of identically treated animals. The percent of tumor regression in these animals was related to the group's average degree of necrosis.
- LPS Lipopolysaccharide
- LPS has long been known to elicit anti-tumor reaction in experimental animals and man. LPS causes acute partial necrosis of certain murine and human tumor transplants in mice and allows one third of the treated animals to completely reject the tumor. The response can be divided into two phases, an early non-immunologic necrosis phase and a subsequent immunologic rejection phase.
- TNS tumor necrosis serum
- TNF is a very efficient inducer of tumor necrosis but is also very toxic to animals. LPS-induced shock seems to be mediated by TNF (B. Beutler et al, Nature 316:552-554, 1985). For the cure of a tumor a mouse seems to have to pay a smaller penalty on toxicity when TNF is administered within TNS than when administered in purified form. TNF kills tumor cells in tissue culture whereas LPS has no effect on cultured tumor cells directly. Our findings suggest LPS acts on tumors through different pathways only one of which is mediated by TNF. In combination the different defense systems are more effective than each by itself. TNS contains other factors which affect the fate of tumors. The increased presence of IL-1 or IL-2 like factors and; of interferon has been identified and indirect evidence suggests the presence of other, as yet unidentified factors.
- TNS has been found to stimulate the activity of NK cells, a cell that kills tumor cells on contact. It induces also the production of substances such as prostaglandins which paralyze the defense capacity of the tumor host.
- Interleukin 1 IL-1
- IL-1 Interleukin 1
- LPS-reactive macrophages facilitates the activation of lymphocytes which are the carriers of the immunological response against tumors.
- IL-1 facilitates the recruitment of lymphocytes, causes them to produce lymphokines which participate in the process of the immune response (such as IL-2 and TRF) and is therefore essential for the generation of effector cells which produce either antibodies to tumor associated surface membrane structures or which seek out tumor cells via these membrane antigens and kill them.
- lymphokines also initiate downregulatory mechanisms which block the immune response. This downregulatory pathway is mediated by cells called suppressor cells, of which suppressor T-cells are the most prominent.
- LPS can be viewed as inducing reactions that inhibit malignant growth (TNF production, enhancement of immune function) and reactions which favor malignant growth (immune suppression). It would appear, that effective immunotherapy must be designed to support the former reaction and to curb the latter.
- Our laboratory has identified negative feedback responses which favor tumor growth and we have demonstrated that these feedback mechanisms can be controlled leading to substantial improvement of tumor rejection.
- Another relevant objective of immunotherapy is the least possible damage caused to the treated tumor host, that is to say low toxicity to the host.
- Tumor necrosis factor is a highly toxic molecule and its therapeutic dose in mice and humans is limited by its lethal effects. This laboratory has established a treatment regimen in which TNF can be applied in low (not toxic) doses in conjunction with other reagents in non toxic doses.
- LPS itself is a good candidate to complement TNF function since LPS induces in the host the release of several lymphokines such as IL-1, IFN, IL-2 and those not identified as yet which may replace LPS.
- LPS presumably through mediators such as IFN causes increased production of prostaglandins (PG) in the tumor host.
- PG prostaglandins
- PG inhibits the function of the immune system (including NK cell activity).
- Inhibition of PG synthesis with Indomethacin increases the tumor rejection induced by TNF and LPS from 30 to 60 percent.
- LPS causes the generation of suppressor cells.
- Suppressor cell activity can be inhibited by administration of cyclophosphamide and this drug given together with TNF, LPS and INDO increases tumor rejection in mice up to 100%.
- LPS Bacterial lipopolysaccharide
- TNF tumor necrosis factor
- TNF tumor necrosis factor
- Effective therapeutic use of TNF is limited, however, by its toxicity.
- We show here, that the efficacy of TNF can be substantially increased by combining its application with low doses of LPS.
- Our data suggests that LPS exerts its anti-tumor effects by engaging more than one defense mechanism.
- Characteristic for the activation of a biological system is a concommitant induction of negative feedback mechanisms which antagonize the initial stimulus. Interference with the negative feedback response may substantially increase biological reactions.
- LPS prostaglandin E
- PGE prostaglandin E
- analogues of LPS in low doses to stimulate the systems to produce natural anti-tumor factors.
- Meth A tumors were maintained in BALB/c mice by weekly passages. For transplants, 10 cells/0.2 ml, were injected intradermally into two sites of the shaved abdominal skin of (BALB/c x C57BL/6) F1 mice with a 30 gauge needle. The grade of tumor necrosis was scored 48 hours after LPS treatment in a grading system consisting of grades 0,1,2 and 3 according to Carswell et al. Proc.Natl. Acad. Sci., Supra. Tumor rejections were scored four weeks later. Grade 3 reflects total or near total necrosis of the tumor, grade 2 covers necrosis areas down to approximately one-half of the tumor, and grade 1, covers all necrosis areas smaller than one-half of the tumor.
- BALB/c mice and (BALB/c x C57BL/6) F1 mice were purchased from Jackson Laboratories, Bar Harbor, Maine.
- TNF or LPS was injected intraveneously. Indomethacin (100 ug/animal) was injected intraveneously together with LPS and/or TNF and subsequently added to the drinking water (20 ug/ml). Cyclophosphamide (30 mg/kg) was injected interperitoneally. Freshly prepared BALB/c mouse serum was injected intraveneously twice, two and 5 days after LPS injection.
- TNF is an effective inducer of tumor necrosis but its therapeutic dose range is small. Substantial degrees of necrosis can be achieved with the injection of 10 ug TNF. There is a rapid decline of necrosis at lower doses. Higher doses were toxic and not administered here. LPS, in a non-toxic dose range, is a less potent inducer of tumor necrosis than purified TNF. Added together, however, the two drugs synergize. They cause a more effective tumor necrotization together than either one of the two substances alone.
- LPS lymphocytes
- IFN interferon
- NK cell activity G. Trinchieri, et al, J. Exp. Med., 147: 1314-1332, 1978; M. Chun et al, J. Exp. Med., 150: 426-431, 1979; M. Chun et al, J. Immunol., 12:331-334, 1981.
- IFN interferon
- Another factor is interleukin-1, a mediator that stimulates the antigen dependent response of lymphocytes (M.K.
- IFN activates NK cells.
- NK cell activation contributes to the response of tumor-bearing mice to LPS, and studied the activation of NK cells in vitro.
- PGE prostaglandin E
- the production of PGE may be blocked with indomethacin (INDO) (H.R. Strausser et al, Int. J. Cancer, 15:724-730, 1975) and suppression of PGE production by INDO increases NK cell activation by IFN 5-50 times (M. Chun et al, J. Scan. Immunol., Supra).
- INDO indomethacin
- LPS alone.
- the degree of necrosis induced with LPS is also increased by treatment of tumor bearing mice with INDO.
- LPS may also stimulate antigen-specific lymphocyte reactions through the release of IL-1 (M.K. Hoffman et al. Nature, 263:416-417, 1976; S.K. Durmm et al. Am. Rev. Immunol., 3 : 262-368 , 1985; M.K. Hoffman et al, J. Immunol., 122:1371-1375, 1979).
- An immune response of T lymphocytes against tumor-associated antigens has been described by Berendt et al. as a consequence of LPS treatment (M.J. Berendt et al, J. Exp. Med., 148:1550-1559, 1978; M.J. Berendt et al, J. Exp.
- Cyclophosphamide (Cy) injected two days after LPS and INDO allows almost all experimental animals to reject their tumors.
- Cy was chosen to delay injection of Cy as compared to the injection of LPS and INDO because preliminary experiments had shown Cy to interfere with the formation of tumor necrosis induced by LPS.
- TNF tumor necrosis factor
- LPS-induced tumor regression are two distinct phases of LPS mediated anti-tumor activities (M.J. Berendt et al, J. Exp. Med., 148:1550-1559, 1978; L.J. Old et al, Current enigmas in cancer research. Lectures, Series 67:273-315, Academic Press, New York and London, 1973), it would appear that TNF mediates only the early phase of tumor necrosis induction.
- TNF may not be the only factor in LPS-induced TNS to account for effective necrotization of tumors because TNF synergizes with LPS also in causing tumor necrosis. It is unlikely that this can be attributed to the release of additional TNF. LPS causes necrosis only in rather high concentrations but synergizes with TNF in low concentrations. This would suggest that in order to produce TNF, LPS is required in high doses, while in low doses it causes the release of factors that synergize with TNF (LPS itself does not act directly on tumor cells) (E.A. Carswell et al, Proc. Nat. Acad. Sci. USA., 72:3666-3670, 1975).
- LPS is thus an extremely effective anti-tumor therapeutic substance in mammals as shown against Meth-A tumor transplants in mice. Its main disadvantage, its toxicity, seems to be related to the production of TNF (B. Beutler et al, Nature, 316:552-554, 1985) whose sufficient production (judged by the degree of necrosis achieved) requires high doses of LPS. When TNF is used from an external source much lower doses of LPS are needed to complement TNF action.
- LPS provides an example as to how these defense systems may interact to achieve an optimized attack against malignancies and the study of LPS action may help in designing new strategies in the treatment of malignancies by activating the body's means of defense in a concerted fashion.
- this method may prove effective when used together with other chemotherapeutic agents or chemical equivalents or variants of the natural agents induced by LPS.
- purified natural TNF, IL-I, IL-2 or IFN may be used or recombinant material.
- combination therapy between LPS and factors whose: release it induces such as TNF, IL-1, IL-2 or IFN is indicated as is combination therapy between factors whose release LPS causes: TNF, IL-1, IL-2, IFN.
- Combination therapy involves direct (TNF) effects on tumor cells and indirect effects (mediated by the immune system). It does not relate to a combined effect of different factors directly on tumor cells such as seen in the synergism between TNF and IFN on L cells in vitro.
- TNF effects may also be shown by other factors with the ability to cause necrosis of tumor cells and which may be released by different cell types.
- LPS effects may also be shown by other microbial or non microbial products which cause the release of immunoregulatory factors in mammals.
- chemotherapeutic agents or natural factors which block the negative feedback inhibition against immune system activation.
- Indomethacin is only one example from a group of prostaglandin inhibitors such as aspirin or Voltaren (Ciba-Geigy Co., Basel, Switzerland).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US86156686A | 1986-05-09 | 1986-05-09 | |
US861566 | 1986-05-09 |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0271521A1 EP0271521A1 (en) | 1988-06-22 |
EP0271521A4 true EP0271521A4 (en) | 1989-11-14 |
Family
ID=25336155
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP19870903576 Withdrawn EP0271521A4 (en) | 1986-05-09 | 1987-05-07 | Lipopolysaccharide and natural factor compositions for anti-tumor therapy and method of treatment. |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0271521A4 (en) |
JP (1) | JPS63503308A (en) |
AU (1) | AU7397887A (en) |
WO (1) | WO1987006830A1 (en) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4844895A (en) * | 1985-11-01 | 1989-07-04 | New York University | Composition containing a peptide fragment of platelet factor four and method for restoring suppressed immune responses |
EP0287633B1 (en) * | 1986-10-16 | 1993-07-07 | The President And Fellows Of Harvard College | Combinations of tumor necrosis factors and anti-inflammatory agents for treating malignant and non-malignant diseases |
US20070025958A1 (en) | 2000-10-27 | 2007-02-01 | Hadden John W | Vaccine immunotherapy |
JP2004521867A (en) | 2000-10-27 | 2004-07-22 | イミュノ−アールエックス, インコーポレイテッド | Vaccine immunotherapy for immunosuppressed patients |
TW200303759A (en) * | 2001-11-27 | 2003-09-16 | Schering Corp | Methods for treating cancer |
AU2002364051A1 (en) * | 2002-01-24 | 2003-09-02 | Children's Medical Center Corporation | Anti-cancer combination and use thereof |
EP1449535B1 (en) * | 2003-02-18 | 2006-05-03 | Clinique La Prairie Research SA | Compositions comprising fetal hemoglobin and bacterial endotoxin and optionally additional fetal liver components |
US20050059613A1 (en) * | 2003-07-08 | 2005-03-17 | Bahram Memarzadeh | Compositions and methods for the enhanced uptake of therapeutic agents through the bladder epithelium |
EP1881080A1 (en) | 2006-07-18 | 2008-01-23 | Institut Gustave Roussy | Toll like receptor 4 dysfunction and the biological applications thereof |
WO2009070639A1 (en) | 2007-11-28 | 2009-06-04 | Irx Therapeutics, Inc. | Method of increasing immunological effect |
DK2429585T3 (en) | 2009-05-15 | 2018-07-30 | Irx Therapeutics Inc | VACCINE IMMUNOTHERAPY |
EP2510106B1 (en) | 2009-12-08 | 2018-02-14 | IRX Therapeutics, Inc. | Method of reversing immune suppression of langerhans cells |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH643138A5 (en) * | 1983-08-29 | 1984-05-30 | Mepha Ag | INDOMETHACIN CONTAINING, gelatinous OINTMENT. |
-
1987
- 1987-05-07 EP EP19870903576 patent/EP0271521A4/en not_active Withdrawn
- 1987-05-07 JP JP50303187A patent/JPS63503308A/en active Pending
- 1987-05-07 WO PCT/US1987/001050 patent/WO1987006830A1/en not_active Application Discontinuation
- 1987-05-07 AU AU73978/87A patent/AU7397887A/en not_active Abandoned
Non-Patent Citations (2)
Title |
---|
No further relevant documents have been disclosed. * |
See also references of WO8706830A1 * |
Also Published As
Publication number | Publication date |
---|---|
JPS63503308A (en) | 1988-12-02 |
EP0271521A1 (en) | 1988-06-22 |
WO1987006830A1 (en) | 1987-11-19 |
AU7397887A (en) | 1987-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5756085A (en) | Use of interleukin-12 to prevent graft versus host disease | |
RU2153332C2 (en) | Method of sensitization of cancer cells to lysis mediated by killer-cells | |
RU2195946C2 (en) | Antitumor therapeutic preparations including the combination of cartilaginous extract and that of antineoplastic agent providing high efficiency at low toxic side effects | |
WO1987006830A1 (en) | Lipopolysaccharide and natural factor compositions for anti-tumor therapy and method of treatment | |
US5961969A (en) | Stable circulating histamine levels | |
Patchen et al. | Betafectin" PGG-glucan | |
EP0303687B1 (en) | Compositions for enhancing adcc therapy | |
Chihara | Preclinical evaluation of lentinan in animal models | |
JP4371437B2 (en) | Treatment method of malignant tumor | |
Chun et al. | Combination immunotherapy of cancer in a mouse model: synergism between tumor necrosis factor and other defense systems | |
Lala et al. | Eradication of spontaneous and experimental adenocarcinoma metastases with chronic indomethacin and intermittent IL‐2 therapy | |
Kleinerman et al. | Effect of L-phenylalanine mustard, adriamycin, actinomycin D, and 4′-(9-acridinylamino) methanesulfon-m-anisidide on naturally occurring human spontaneous monocyte-mediated cytotoxicity | |
Wu et al. | Radioprotection of C3H mice by recombinant human interleukin-1α | |
Bloksma et al. | Synergistic action of human recombinant tumor necrosis factor with endotoxins or nontoxic poly A: U against solid Meth A tumors in mice | |
佐々木琢磨 et al. | Antitumor activity and immunomodulatory effect of glycoprotein fraction from scallop Patinopecten yessoensis. | |
Saijo et al. | In vivo and in vitro effects of Nocardia rubra cell wall skeleton on natural killer activity in mice | |
Matsumori et al. | Immunomodulating therapy in experimental myocarditis | |
JPS62263127A (en) | Remedy for tumor by self-derived lak cell, interleukin-2 andornithine decarboxylase inhibitor | |
JPH09510737A (en) | Use of IL-4 to enhance chemotherapeutic agents | |
Krosnick et al. | Studies of the mechanisms of toxicity of the administration of recombinant tumor necrosis factor α in normal and tumor-bearing mice | |
Schindler et al. | Stimulatory effects of muramyl dipeptide and its butyl ester derivative on the proliferation and activation of macrophages in vitro | |
Kedar et al. | Suppression by tumor growth of T cell growth factor production in mouse lymphoid cell cultures | |
Jones et al. | Absence of generalized immunosuppression in C57BL/6J mice implanted with Lewis T241 fibrosarcoma or Lewis lung carcinoma | |
CN114848681A (en) | Immunotherapy composition and application thereof | |
WO1991012849A1 (en) | Engrafting allogeneic tissues or organs using interleukin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE FR GB IT LI LU NL SE |
|
17P | Request for examination filed |
Effective date: 19880509 |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 19891114 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 19900117 |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: CHUN, MYUNG Inventor name: HOFFMANN, MICHAEL, K. Inventor name: HAMMERLING, ULRICH |